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The contribution of the complement system in the pathophysiology of brain cancers
has been recently considered in light of its well-known involvement in carcinogenesis.
Complement system represents an important component of the inflammatory response,
which acts as a functional bridge between the innate and adaptive immune response.
C1q, the first recognition subcomponent of the complement classical pathway, has
recently been shown to be involved in a range of pathophysiological functions that are
not dependent on complement activation. C1q is expressed in the microenvironment
of various types of human tumors, including melanoma, prostate, mesothelioma, and
ovarian cancers, where it can exert a protective or a harmful effect on cancer progression.
Despite local synthesis of C1q in the central nervous system, the involvement of
C1q in glioma pathogenesis has been poorly investigated. We, therefore, performed
a bioinformatics analysis, using Oncomine dataset and UALCAN database in order to
assess whether the expression of the genes encoding for the three chains of C1q
(C1qA, C1qB, and C1qC) could serve as a potential prognostic marker for gliomas.
The obtained results were then validated using an independent glioma cohort from
the Chinese Glioma Genome Atlas datasets. Our bioinformatics analysis, coupled with
immunohistochemistry and fluorescence microscopy, appears to suggest a positive
correlation between higher levels of C1q expression and unfavorable prognosis in a
diverse grade of gliomas.
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INTRODUCTION
The complement protein C1q represents the recognition subcomponent of the complement
classical pathway, which is responsible for clearing immune complexes and invading pathogens.
Its association with C1r and C1s, following ligand recognition, triggers complement activation
(1, 2). C1q is characterized by a typical tulip-like overall structure, assembled from 18
polypeptide chains of three different types, A (28 kDa), B (25 kDa), and C (24 kDa),
each having an N-terminal collagen-like domain and a C-terminal globular (gC1q) domain
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(3, 4). The gC1q domain, which is the ligand recognition region
of C1q, has a heterotrimeric structure, being composed of C-
terminal ends of A, B, and C chains (5). In addition to binding
IgG and IgM containing immune complexes and activating the
complement classical pathway, there is emerging evidence to
suggest that C1q plays crucial roles in several processes that
are independent of complement activation, such as placentation
(6), angiogenesis (7), autoimmunity (8, 9), and carcinogenesis
(9, 10). C1q is highly expressed in the microenvironment of
various types of human tumors (10, 11) where it can exert
either a protective or a detrimental effect on the tumor growth.
In prostate cancer cells, C1q was recently shown to induce
apoptosis by activating the tumor suppressor WOX1 (12), thus
acting as an anti-tumor humoral factor. In ovarian cancer,
C1q has been shown to induce apoptosis in a representative
SKOV3 cell line via activation of TNF-α, upregulation of
Fas, and downregulation of mammalian target of rapamycin,
RICTOR, and RAPTOR survival pathways (13). In a BALB-
neuT mouse model of mammary carcinomas, C1q was shown to
have a protective role against cancer progression (14). However,
C1q can promote adhesion, migration, and proliferation of
primary cells derived from malignant pleural mesothelioma
patients, a relatively rare disease associated with exposure to
asbestos (11). This dichotomous role of C1q has been further
highlighted by a bioinformatics analysis involving several types
of carcinomas (15).
The importance of C1q in the pathophysiology of the central
nervous system (CNS) has been an area of intense research
in the last two decades. In a healthy brain, C1q promotes
synapse elimination required for fine circuitry refinement during
CNS development (16). C1q activities, unrelated to complement
activation, were shown to support neuronal survival and neurite
outgrowth in vitro and protect against β-amyloid-mediated
neurotoxicity (17). C1q can also interact with abnormal protein
aggregates, such as βA1-42, thus favoring neurodegenerative
diseases progression (18).
Since C1q and other complement components can be locally
produced within the CNS by microglia and astrocytes, it
is likely that C1q has involvement in primary brain tumor
pathophysiology (19). Brain malignancies arise from cells of the
CNS and are classified according to the tissue of phylogenetic
origin. Gliomas represent the most common and aggressive form
of brain tumors in adults; they are derived from glial or precursor
cells (20). These are a heterogeneous group of diseases with
multiple subtypes (20, 21). Glioblastoma multiforme (GBM) is
the most common and fatal form of the primary brain tumor,
accounting for approximately 60% of all glioma cases (22),
whereas low-grade gliomas (LGGs) are the secondmost common
type of glioma in adults (∼30%) (22).
In GBM tumor specimens, the presence of C1q does
not correlate with CD45 positive leukocytic infiltration (23).
Interestingly, C1q appeared to be highly concentrated around
the malignant cells and the necrotic debris. Moreover, the
serum concentration of C1q, together with critical components
of the lectin and alternative complement pathways, appeared
significantly increased in GBM patients as compared to healthy
controls (23), thus indicating a role for complement activation in
the pathogenesis of the GBM.
In the current study, we performed a bioinformatics analysis
aimed at investigating whether C1q can serve as a potential
prognostic marker for gliomas.
MATERIALS AND METHODS
Oncomine Database Analysis
The expression levels of C1qA, C1qB, and C1qC genes in gliomas
were analyzed using Oncomine (www.oncomine.org), a cancer
microarray database and web-based data mining platform for
new discovery from genome-wide expression analyses (24, 25).
We compared the differences in mRNA levels between normal
tissue and cancer. The mRNA expression level in neoplastic
tissues, compared to the healthy tissues, was obtained as the
parameters of P < 0.05, fold change > 2, and gene ranking in
the top 10%. Information about the datasets used in this study is
summarized in Table 1.
UALCAN and CGGA Database Analysis
UALCAN (http://ualcan.path.uab.edu) is a web resource for
analyzing cancer transcriptome data, which estimates the effect
of gene expression level on the patient survival (26). In addition
to the gene expression variation across tumor samples, gene-
level correlations with patient survival also feature in UALCAN.
Available genomics data from “The Cancer Genome Atlas”
(TCGA) project was used for Kaplan–Meier survival analysis
to generate survival probability plots (26). The prognostic
significance of C1qA, C1qB, and C1qC expression and survival
in gliomas were analyzed by UALCAN. The hazard ratio
with 95% confidence intervals and logrank p-value were
also computed.
The Chinese Glioma Genome Atlas (CGGA) (http://www.
cgga.org.cn) is a user-friendly web application for data storage
and analysis exploring brain tumors datasets from Chinese
cohorts (Table 1) (27). Analyze tool of CGGA was used to
browse C1qA, C1qB, and C1qC mRNA expression profile and to
perform survival analysis in specific glioma subtype. The hazard
ratio with 95% confidence intervals and logrank p-value were
also computed.
Statistical Analysis
Survival curves were generated by UALCAN and CGGA. All
results are displayed with p-values from a log-rank test. P-
values <0.05 were considered significant. Similarly, in the case
of Oncomine, the program provided the statistical significance of
data (P-values).
Immunostaining
Tissue samples, derived from the neuroepithelial tumors with
astrocytic differentiation, presenting different grades (grade-
II and -III to GBM, grade-IV), were collected from glioma
patients, after informed consent following approval of the ethical
considerations by the Institutional Board of the University
Hospital of Trieste, Italy.
Gliomas tissue specimens (five patients for each glioma grade,
Department of human pathology of the University Hospital of
Cattinara, Trieste, Italy) were fixed in 10% v/v buffered formalin
and paraffin embedded. For immunostaining, 4 µm-thick tissue
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TABLE 1 | Characteristics of the datasets used in bioinformatics analysis.
Datasets Study description Experiment type
Sun brain One hundred fifty-seven (157) brain and CNS tumors and 23 normal brain samples were analyzed on Affymetrix U133 Plus
2.0 microarrays. Sample data includes type, grade, and sample name. Corresponding DNA copy number data is available
in Kotliarov Brain
mRNA
French brain Twenty-three (23) anaplastic oligodendroglioma, 4 anaplastic oligoastrocytoma, and 6 normal brain samples were analyzed
on Affymetrix U133 Plus 2.0 microarrays. Sample data includes 10q loss of heterozygosity, 19q loss of heterozygosity, 1p
loss of heterozygosity, age, chemotherapy response, EGFR amplification, sex, survival after diagnosis, survival after surgical
resection, and therapy
mRNA
TCGA brain Five hundred forty-seven (547) glioblastoma and 10 normal brain samples were analyzed. Sample data includes age, sex,
survival, and others. This dataset consists of Level 2 (processed) data from the TCGA data portal. Corresponding DNA copy
number data is available in TCGA Brain 2
mRNA
CGGA brain The CGGA RNA sequence dataset consisted of 325 samples, including 109 grade-II samples, 72 grade-III samples and
144 grade-IV samples. Of the 144 GBM samples, 6 samples were lost to follow-up; therefore, 138 samples were included
in the survival analysis. The patients with GBM were followed up every 3 months
mRNA
Rickman brain Forty-five (45) astrocytoma and 6 normal temporal lobe samples were analyzed on Affymetrix HuGeneFL microarrays.
Sample data include type and grade
mRNA
Bredel brain 2 Fifty (50) brain CNS carcinoma samples and 4 normal brain samples were analyzed on cDNA microarrays. Sample data
includes disease type
mRNA
Liang brain Thirty (29) glioblastoma, 3 mixed astrocytoma-oligodendroglioma, 2 oligodendroglioma, 2 normal brain, and 1 normal
cerebellum sample were analyzed on cDNA microarrays. Sample data includes type, age, location, primary/recurrent, sex,
and survival
mRNA
sections were de-waxed with two changes of xylene, 10min each.
Slides were then transferred to 100% alcohol, for two changes,
10min each, and once through 95 and 70% alcohol respectively,
for 5min each. Finally, they were rinsed in de-ionized water,
twice for 3min each. The antigen unmasking technique was
performed using Novocastra Epitope Retrieval Solutions pH9
EDTA-based buffer in thermostatic bath at 98◦C for 30min (28).
Sections were brought to room temperature and washed in PBS.
Subsequently, the neutralization of the endogenous peroxidase
with 3% v/v H2O2 and Fc blocking by a specific protein block
(Novocastra, Leica Biosystems) were performed.
For immunostaining, glioma sections were probed with the
following primary antibodies overnight at 4◦C: rabbit anti-
human C1q polyclonal antibody (1:500; Dako), rabbit anti-
human C3d polyclonal antibody (1:100; Cell Marque) and rabbit
anti-human C4d polyclonal antibody (1:100; Cell Marque).
Antibody-Antigen recognition was detected using Novolink
Polymer Detection Systems (Novocastra Leica Biosystems,
Newcastle) and employing the high sensitivity AEC (3-Amino-
9-Ethylcarbazole) as chromogen. Slides were counterstained
with Harris Haematoxylin (Novocastra, Ltd) and images
were collected using a Leica DFC320 digital camera (Leica
Microsystems, Wetzlar, Germany).
For double immunostaining experiments, tissue sections
were incubated overnight at 4◦C with the following primary
antibodies: rabbit anti-human C1q polyclonal antibody (1:500,
Dako), mouse anti-human CD68 (1:50, Clone KP1, Dako)
and anti-human CD163 monoclonal antibodies (1:100, Clone
10D6, Leica Biosystems). The following secondary antibodies
were used: goat anti-rabbit conjugated to Alexa Fluor 488,
and goat anti-mouse conjugated to Alexa Fluor 568 (Life
Technologies). Nuclei were counter-stained with DAPI (4′,6-
diamidin-2-fenilindolo). All the sections were analyzed under
Zeiss Axio Scope A1 optical microscope (Zeiss, Germany) and
microphotographs were collected using an Axiocam 503 Color
digital camera with the ZEN2 imaging software (Zeiss Germany).
RESULTS
Bioinformatics Analysis Reveals Higher
mRNA Levels of C1q A, B, and C Chains in
Gliomas
We initially compared the mRNA levels of the three chains
of human C1q (A, B, and C) in normal brain and gliomas
using the Oncomine platform. From the analysis performed on
several datasets such as Sun’s, French’s, TCGA’s, Rickman’s, Bredel
2’s, and Liang’s, a significantly higher mRNA expression levels
for C1qA, C1qB, and C1qC chains were detected in gliomas
(different histotypes and grades) as compared to normal brain
tissue (Figure 1, P < 0.05; Table 2).
We then took advantage of the UALCAN tool to carry
out bioinformatics analysis on C1qA, C1qB, and C1qC mRNA
expression levels according to TCGA database. UALCAN tool
considers LLGs, grade-II and -III, and high-grade gliomas
(HGGs) only grade-IV (or GBM) while the World Health
Organization (WHO) considers as LLGs, grade-I and -II, and
HGGs as grade-III and -IV. Based on this analysis, as shown in
Figure 2, a positive correlation between the mRNA expression
of the three chains and the unfavorable prognosis only in LGGs
(grade-II and -III) was evident, where the survival probability
is indeed reduced (P < 0.05). By contrast, no correlation was
observed between C1qA, C1qB, and C1qCmRNA expression and
the survival probability in GBMs (grade-IV) (Figure 2).
To further validate these results, we used the CGGA tool to
inquire an independent glioma database. Based on this analysis,
a positive correlation was found between the mRNA expression
of the three C1q chains and the unfavorable prognosis in
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FIGURE 1 | C1qA, C1qB, and C1qC expression in gliomas. Sun’s dataset was used for bioinformatics analysis to explore C1qA and C1qB mRNAs expression in the
glioblastoma multiforme, whereas Bredel 2’s dataset was used for bioinformatics analysis to evaluate C1qC mRNA. A higher expression of the three chains was
detectable in glioblastoma multiforme compared to normal brain tissue. GBM, glioblastoma multiforme.
TABLE 2 | C1qA, C1qB, and C1qC expression in gliomas in the datasets used in
the current study with Oncomine.
Datasets C1q
chains
Brain vs. tumor P-value
Sun C1qA
C1qB
Brain (23) vs. Anaplastic astrocytoma (grade-III) (19)
Brain (23) vs. Glioblastoma multiforme (grade-IV)
(81)
Brain (23) vs. Anaplastic astrocytoma (grade-III) (19)
Brain (23) vs. Glioblastoma multiforme
(grade-IV) (81)
3.59E-6
1.21E-19
5.22E-6
4.27E-14
French C1qA
C1qB
Brain (6) vs. Anaplastic oligoastrocytoma (grade-III)
(4)
Brain (6) vs. Anaplastic oligodendroglioma (grade-III)
(23)
Brain (6) vs. Anaplastic oligoastrocytoma
(grade-III) (4)
8.89E-4
3.59E-6
5.89E-4
TCGA C1qA Brain (10) vs. Glioblastoma multiforme (grade-IV)
(542)
1.63E-8
C1qB Brain (10) vs. Glioblastoma multiforme (grade-IV)
(542)
3.45E-4
Richman C1qB Temporal lobe (10) vs. Astrocytoma (different grade)
(45)
7.87E-4
Bredel 2 C1qC Brain (4) vs. Glioblastoma multiforme (grade-IV) (28) 5.23E-13
Liang C1qC Brain (2) vs. Glioblastoma multiforme (grade-IV) (30) 2.12E-4
n, samples number.
all WHO grade of gliomas, where the survival probability is
indeed reduced (P < 0.05) (Figure 3, lowest panels). A similar
unfavorable prognostic effect was detected in grade-III gliomas
(P <0.05) while no correlation was observed between C1qA,
C1qB, and C1qC mRNA expression and the survival probability
in gliomas grade-II (Figure 3). In contrast to UALCAN analysis,
a negative prognostic effect was underscored in GBMs (P < 0.05)
(Figure 3).
Low- and High-Grade Gliomas Abundantly
Express C1q Protein
We investigated the presence and the distribution of C1q in
several glioma samples of different grades. As shown in Figure 4,
a high expression level of C1q was observed both in LGGs as well
as GBM.
Within the tumor-associated microenvironment, C1q was
mainly expressed by monocytoid cells, suggestive of tumor
associated macrophages (arrow heads) scattered among the
neoplastic cells, which show an increased density around the
intra-tumoral necrotic foci (Figure 4C). Moreover, the presence
of C1q was detected in association with the vascular stroma;
in GBM, it was also expressed in the vascular endothelial
cells (Figures 4E,F). C1q deposition was not associated with
complement activation, occurring either via the classical or the
other pathways, since we failed to observe any C3d and C4d
immunoreactivity in our glioma’s specimens (Figure 5).
Infiltrating M2 Macrophages Are Likely
Source of C1q in Gliomas
To further characterize the cell type infiltrating the tumor
and actively involved in C1q synthesis, immunocytochemical
experiments were performed on gliomas specimens via staining
for C1q and CD68, a specific marker for monocyte/macrophage
cell types. A clear co-localization of C1q/CD68 immunoreactivity
was detected in both low- and high-grade gliomas (Figure 6),
thus identifying the macrophages infiltrating glioma tumor as the
main source of local C1q synthesis and secretion. Double labeling
experiments were also performed using an anti-CD163, a specific
marker for the tumor-promoting M2-polarized macrophages
(Figure 7). Under these conditions, it appeared that not only the
number of CD163 positive cells, but also the CD163 expression
level itself, were increased in high-grade gliomas as compared to
low-grade ones. Most of the C1q labeled cells colocalized with
CD163, even though a small fraction of infiltrating cells were
solely expressing C1q, suggesting that theymay correspond to the
CD68/C1q co-expressing M1-type of macrophages.
DISCUSSION
Glial tumors, also called gliomas, are the most prevalent form
of adult brain tumor, accounting for nearly 80% of all brain
malignancies (22). Based on their histological features and
expression of lineage markers, gliomas can be classified into
astrocytomas, oligodendrogliomas, ependymomas, and choroid
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FIGURE 2 | Pathological significance of C1q expression in gliomas. According to the UALCAN database analysis, C1qA, C1qB, and C1qC mRNAs expression were
negatively linked to a survival probability in patients with LGGs (grade-II and -III) (A), whereas no correlation in patients with GBM (grade-IV) (B). LGGs, low-grade
gliomas; GBM, glioblastoma multiforme.
plexus tumors (29). Astrocytomas, which represent almost half
of all primary brain and spinal cord tumors, may occur in the
brain with a preferential localization in the cerebrum and affect
mostly adults, particularly middle-aged men. In 2016, the WHO
has redefined this classification scheme by introducing molecular
parameters in addition to the well-established histopathological
features (20, 21). These new guidelines have allowed classification
of all pathological glial entities in four grades, according
to histological parameters including nuclear atypia, mitoses,
vascular proliferation, and necrosis. According to the grading
system, astrocytic neoplasm can be divided into low and
high-grade astrocytomas. Low-grade astrocytomas are the least
malignant tumors characterized by slow growth and good
prognosis being the pilocytic astrocytomas (grade-I) and diffuse
astrocytomas (grade-II), the most frequent types. High-grade
astrocytomas are glial tumors presenting a rapid growth with
a tendency to infiltrate nearby brain tissues. They are divided
into astrocytomas grade-III (anaplastic astrocytoma) and grade-
IV (glioblastoma multiforme, GBM). GBM is the most aggressive
and fast-growing malignancy characterized by poor clinical
outcome. It can arise in the brain de novo, or it can evolve from
lower-grade astrocytomas or oligodendrogliomas (29). Recent
studies have begun to address the immune signature of the
glioma microenvironment and its relationship with prognosis
(30). The fact that C1q can be locally synthesized within the
CNS and that it is involved in tumor immunology, we wanted
to interrogate its relevance in the pathogenesis and prognosis
of gliomas.
In the current study, we performed a bioinformatics analysis
to unveil whether C1q could serve as a potential prognostic
marker for these devastating malignancies. UALCAN queries of
the TCGA and the CGGA datasets were analyzed to validate
our initial result. It highlighted a significant correlation between
high expression level of the three chains of the C1q and
poor prognosis in gliomas of diverse grade of malignancy
(Figures 2, 3). In particular, while interrogating the CGGA
dataset, which allowed distinction between grade-II and grade-
III gliomas, a significant correlation was established only for
grade-III gliomas (Figure 3). In the TCGA dataset, significance
was achieved for the so-called LGGs, which combines grade-II
and -III cases (Figure 2). The main contradiction was noticed
in GBMs (grade-IV gliomas), where opposite prognostic effects
were underscored in relation to the dataset used (Figures 2, 3).
One possible explanation for these contradictory observations
may originate from the algorithm utilized by the bioinformatics
web resources to define high and low expression profile of
the genes. Another aspect to take into account is potential
differences in the genetic and epigenetic signatures characterizing
the two datasets, the TGCA mostly relying on Caucasian
patients while CGGA relying on Chinese cohorts. Indeed, it
has been proven that substantial variation in glioma incidence
and survival are connected, to some extent, to race and
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FIGURE 3 | Pathological significance of C1q expression in gliomas. According to the CGGA database analysis, C1qA, C1qB, and C1qC mRNAs expression were
negatively linked to a survival probability in patients with grade-III and GBM. H, high expression; L, low expression.
ethnicity (31). Finally, it is worth mentioning that GBM
exists in two forms, primary and secondary, indistinguishable
histologically, but clearly discernible clinically and in terms
of molecular signatures (29, 32). Primary GBM is the most
common form that occurs mainly in adults over 50 years of
age. The genetic profile is characterized by epidermal growth
factor receptor (EGFR) overexpression, phosphatase and tensin
homolog (PTEN) mutation, p16 deletion, and chromosome
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FIGURE 4 | Representative immunohistochemical analysis of C1q in low (A,B) and high grade (C,D) gliomas showing a high expression in both histotypes regardless
of grade. C1q results mainly expressed by macrophages and the vascular stroma (see arrows). C1q expression in the endothelial cells is shown in panels (E,F) (see
arrows, low, and high magnification). Polymer detection system with AEC (red) chromogen; scale bars, 50µm.
10 loss (32). Secondary GBM derives from a malignant
progression of diffuse or anaplastic astrocytomas (grade-II and -
III, respectively), and occurs in younger patients, characterized by
p53 mutation and a reduced state of heterozygosity in tumor cells
(loss of heterozygosity) on chromosome 10q (32). Both datasets
used in our bioinformatics analysis did not discriminate between
de novo and secondary GBM, possibly masking a significant
correlation, indeed expected, in those tumors progressing from
grade-III gliomas.
There is emerging evidence to confirm that C1q is involved
in cancer pathophysiology, being an important modulator of
inflammation and cytokine/chemokine/growth factor secretion.
What is still quite puzzling is whether and when C1q is
protective against or supportive of cancer progression. On
one hand, C1q can be detrimental to cancer cell viability via
its cell lytic, anaphylatoxin, and opsonin effector mechanisms
(33). Alternatively, C1q can exert tumor-promoting functions
which are independent of the classical pathway activation. As
observed for other types of cancers (10, 15), C1q deposition in
gliomas seems not to be correlated with complement activation
as we were unable to detect the complement split products
C3d and C4d in the cohort of tumor specimens tested (n =
5). It is worth noting that our conclusions are based on the
use of only five patients’ tissue samples that were subjected
to immunohistochemistry. This is in contrast to other cancers
such as renal and lung cancers, where C4d deposition has
been reported (34, 35). The mechanisms underlying such binary
features of C1q are likely to be shaped by the type of cancer
cells, nature and extent of infiltrating immune cells and their
ability to synthesize locally C1q (and/or other complement
components), and most crucially, the biochemical nature of the
tumor microenvironment.
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FIGURE 5 | Representative immunohistochemical analysis of C3d and C4d complement activation products in low grade (A,D) and high grade (B,E) gliomas. C3d
and C4d specific staining is segregated in the blood vessels, while the tumor tissues are negative. Liver staining (C,F) represents the antigen (tissue) control. Polymer
detection system with AEC (red) chromogen; scale bars, 50µm.
FIGURE 6 | Representative microphotographs of double immunofluorescence for C1q (green signal) and CD68 (red signal) in FFPE sections of low (A) and high (B)
grade gliomas confirming the macrophage nature of C1q expressing monocytoid elements. The cell nuclei were stained with DAPI; scale bars, 10µm.
Frontiers in Immunology | www.frontiersin.org 8 October 2019 | Volume 10 | Article 2366
Mangogna et al. Prognostic Significance of C1q in Gliomas
FIGURE 7 | Representative microphotographs of double immunofluorescence for C1q (red signal) and CD163 (green signal) in FFPE sections of low (A) and high (B)
grade gliomas confirming the M2-polarization of macrophages expressing C1q. The cell nuclei were stained with DAPI; scale bars, 10µm.
In the brain, complement components, including C1q,
can be locally produced by resident neurons and glial
cells, microglia and astrocytes being the major producers
(19, 36). Our immunocytochemical data demonstrated that
CD68 and CD163 positive infiltrating cells represent the
cell types actively synthesizing C1q in the tumor micro-
environment (Figures 6, 7). CD68 expression is characteristic
of tumor-associated macrophages, whose enrichment in
glioma has been associated with poor prognosis (37). CD163
identify the M2-polarized macrophages, which are highly
versatile cells known to influence multiple steps in tumor
development and invasiveness along with angiogenesis and
immunosuppression (38).
These cells in the brain are derived from two different
sources: resident microglia and monocytes/macrophages
that enter the brain from bone marrow. Even though it is
quite difficult to distinguish between these two different
cell types due to the lack of available definitive markers,
they are recruited by the tumor microenvironment via
several gliomas derived chemokines that also contribute to
their polarization from a tumor-suppressive to a tumor-
promoting phenotype (39). It is interesting to note that
C1q has been shown to enhance the secretion and action
of these chemokines (40, 41). Therefore, C1q produced and
released by microglia/macrophage cells, is expected to promote
immunosuppression, thus favoring glioma cell proliferation.
This is consistent with our observation linking the expression
of the three chains of human C1q with an unfavorable
prognosis in grade-II and -III gliomas (LGGs) in TCGA
dataset and in grade-III gliomas in CGGA dataset, respectively
(Figures 2, 3).
We also observed a high degree of deposition of C1q in the
perivascular stroma as well as on endothelial cells belonging to
the tumor vasculature. Developing gliomas require an increased
nutrient supply and hence trigger neovascularization via the
release of angiogenetic factors by cancer cells. C1q itself
promotes angiogenesis through its globular heads (7). Massive
angiogenesis is induced by regions of hypoxia within the tumor
that are not only loci generating damage-associated molecular
patterns (DAMPs), recognized by C1q but also privileged
sites for glioma stem-like cell (GSC) settlement (42). These
cells are quite dangerous since they maintain tumor growth
through self-renewal amidst a supportive microenvironment.
C1q, in this context, has been shown to participate in
GSC maintenance and expansion via the activation of the
canonical Wnt signaling cascade through its binding to
Frizzled-receptor (43).
Our bioinformatics study, based solely on mRNA expression
dataset and therefore further requiring a validation at the
protein level, underlines how complex, multifaceted and yet
feebly understood is the differential role of C1q in tumor
progression or suppression. In conclusion, C1q plays a
fundamental role in the pathogenesis of gliomas, but further
investigation is required for its use in the clinic as a
prognostic marker.
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